Zacks Investment Research
03 Aug 2026, 12:46 UTC · 1h ago
Indivior Pharmaceuticals Inc. (INDV) Q2 Earnings and Revenues Beat Estimates
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
03 Aug 2026, 12:46 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Indivior Pharmaceuticals Inc. (INDV) reported quarterly earnings of $1.15 per share, beating the Zacks Consensus Estimate of $0.97. — An earnings beat of 18.56% typically drives positive short-term price action for the specific ticker.
+0.40Indivior Pharmaceuticals reported quarterly revenues of $343 million, surpassing consensus estimates by 11.36%. — Top-line growth and a revenue beat confirm operational strength and support the earnings beat.
+0.30Indivior Pharmaceuticals has surpassed consensus EPS and revenue estimates for four consecutive quarters. — A consistent track record of beats suggests reliable management execution and potential for further upward revisions.
+0.20Which stocks this story touches
Continue reading
6 related stories
Top 2 movers · tap to explore
The company beat both earnings and revenue estimates, showing strong year-over-year growth and a positive earnings surprise.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
1h ago
